We Can See Tumor Heterogeneity. Now What? We Ask Cathy Smith, UCSF

Mendelspod Podcast

Content provided by Mendelspod Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mendelspod Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

4+ y ago

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on August 29, 2022 10:12 (1+ y ago). Last successful fetch was on July 07, 2022 16:01 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Cathy Smith counts herself among the Gleevec Generation after the landmark targeted cancer therapy. She’s an optimist who believes in the possibilities of precision medicine. “We are outsmarting cancer,” she says. Cathy is an Assistant Professor of Hematology/Oncology at UCSF where she is also an MD treating patients. Her area of expertise is in acute myeloid leukemia or AML. She joins us today to discuss a recent group paper and collaboration using new technology to track and monitor cancer evolution at the single cell level.

398 episodes

#Genetic Testing #Biology #Science #Natural Sciences